0001171000-15-000110.txt : 20151124 0001171000-15-000110.hdr.sgml : 20151124 20151124155715 ACCESSION NUMBER: 0001171000-15-000110 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151123 FILED AS OF DATE: 20151124 DATE AS OF CHANGE: 20151124 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nexvet Biopharma plc CENTRAL INDEX KEY: 0001618561 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 BUSINESS PHONE: 353 1 215 8100 MAIL ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 FORMER COMPANY: FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd DATE OF NAME CHANGE: 20140903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GEARING DAVID CENTRAL INDEX KEY: 0001632481 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36828 FILM NUMBER: 151252655 MAIL ADDRESS: STREET 1: C/O NEXVET BIOPHARMA PLC STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK STATE: L2 ZIP: 00000 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2015-11-23 0001618561 Nexvet Biopharma plc NVET 0001632481 GEARING DAVID C/O NEXVET BIOPHARMA PLC UNIT 5, SRAGH TECHNOLOGY PARK,RAHAN ROAD TULLAMORE , CO. OFFALY L2 R35 FR98 IRELAND 0 1 0 0 Chief Scientific Officer Ordinary Shares 2015-11-23 4 M 0 5600 .125 A 279330 I By Gearing Family Pty Ltd <Gearing Family A/C> Ordinary Shares 5600 D Ordinary Shares 83664 I By DJGearing Pty Ltd <Gearing Family Superannuation Fund A/C> Options to purchase shares .125 2015-11-23 4 M 0 5600 0 D 2019-07-01 Ordinary Shares 5600 7466 I By Gearing Family Pty Ltd <Gearing Family A/C> The reporting person and his spouse have shared voting and dispositive power with respect to these reported securities. 5,600 options to purchase shares vested and became exercisable on 11/19/15 after the Issuer's board of directors determined that there had been successful completion of an efficacy trial for an Issuer product. A further 3,733 options will vest and be exercisable on each of 7/1/16 and 1/1/17. /s/ David Gearing by Geraldine T. Farrell, Attorney-in-Fact 2015-11-23